Sökning: onr:"swepub:oai:DiVA.org:uu-65946" >
Transforming growth...
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment : results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
-
- Hallberg, Pär (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Osteoporos,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
- Lind, Lars (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Sciences, Uppsala University, Uppsala, Sweden; AstraZeneca Research & Development, Mölndal, Sweden
-
- Billberger, Katarina (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Osteoporos,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
visa fler...
-
- Michaëlsson, Karl (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Orthopaedics,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
-
- Karlsson, Julia (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Osteoporos,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
- Kurland, Lisa, 1960- (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
- Kahan, Thomas (författare)
- Karolinska Institutet
-
- Malmqvist, Karin (författare)
- Karolinska Institutet
-
- Öhman, K. Peter (författare)
- AstraZeneca Research & Development, Mölndal, Sweden; Department of Medicine and Care, Faculty of Health Sciences, Linköping, Sweden
-
- Nyström, Fredrik, 1963- (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US
-
- Liljedahl, Ulrika (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
- Syvänen, Ann-Christne (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
- Melhus, Håkan (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Osteoporos,Department of Medical Sciences, Uppsala University, Uppsala, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2006-12-05
- 2004
- Engelska.
-
Ingår i: Clinical Cardiology. - : Wiley. - 0160-9289 .- 1932-8737. ; 27:3, s. 169-73
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Angiotensin II, via the angiotensin II type 1 (AT1) receptor, may mediate myocardial fibrosis and myocyte hypertrophy seen in hypertensive left ventricular (LV) hypertrophy through production of transforming growth factor beta1 (TGF-beta1); AT1-receptor antagonists reverse these changes. The TGF-beta1 G + 915C polymorphism is associated with interindividual variation in TGF-beta1 production. No study has yet determined the impact of this polymorphism on the response to antihypertensive treatment. HYPOTHESIS: We aimed to determine whether the TGF-beta1 G + 915C polymorphism was related to change in LV mass during antihypertensive treatment with either an AT1-receptor antagonists or a beta1-adrenoceptor blocker. The polymorphism was hypothesized to have an impact mainly on the irbesartan group. METHODS: We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol. RESULTS: Irbesartan-treated patients who were carriers of the C-allele, which is associated with low expression of TGF-beta1, responded with a markedly greater decrease in LV mass index (LVMI) than subjects with the G/G genotype (adjusted mean change in LVMI -44.7 g/m2 vs. -22.2 g/m2, p = 0.007), independent of blood pressure reduction. No association between genotype and change in LVMI was observed in the atenolol group. CONCLUSIONS: The TGF-beta1 G + 915C polymorphism is related to the change in LVMI in response to antihypertensive treatment with the AT1-receptor antagonist irbesartan.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Antihypertensive Agents/*therapeutic use
- Atenolol/therapeutic use
- Biphenyl Compounds/*therapeutic use
- Double-Blind Method
- Female
- Genotype
- Humans
- Hypertension/complications/*drug therapy
- Hypertrophy; Left Ventricular/complications/*drug therapy/physiopathology
- Linear Models
- Male
- Polymorphism; Genetic
- Research Support; Non-U.S. Gov't
- Sweden
- Tetrazoles/*therapeutic use
- Transforming
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hallberg, Pär
-
Lind, Lars
-
Billberger, Kata ...
-
Michaëlsson, Kar ...
-
Karlsson, Julia
-
Kurland, Lisa, 1 ...
-
visa fler...
-
Kahan, Thomas
-
Malmqvist, Karin
-
Öhman, K. Peter
-
Nyström, Fredrik ...
-
Liljedahl, Ulrik ...
-
Syvänen, Ann-Chr ...
-
Melhus, Håkan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Clinical Cardiol ...
- Av lärosätet
-
Uppsala universitet
-
Örebro universitet
-
Karolinska Institutet
-
Linköpings universitet